SI2714740T1 - Nevtralizirajoče protitelo Mat3 receptorja prolaktina in njegova terapevtska uporaba - Google Patents
Nevtralizirajoče protitelo Mat3 receptorja prolaktina in njegova terapevtska uporabaInfo
- Publication number
- SI2714740T1 SI2714740T1 SI201230553A SI201230553A SI2714740T1 SI 2714740 T1 SI2714740 T1 SI 2714740T1 SI 201230553 A SI201230553 A SI 201230553A SI 201230553 A SI201230553 A SI 201230553A SI 2714740 T1 SI2714740 T1 SI 2714740T1
- Authority
- SI
- Slovenia
- Prior art keywords
- therapeutic use
- receptor antibody
- prolactin receptor
- antibody mat3
- neutralizing prolactin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168644A EP2530089A1 (en) | 2011-06-03 | 2011-06-03 | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| PCT/EP2012/060078 WO2012163932A1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
| EP12729030.2A EP2714740B1 (en) | 2011-06-03 | 2012-05-31 | Neutralizing prolactin receptor antibody mat3 and its therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2714740T1 true SI2714740T1 (sl) | 2016-06-30 |
Family
ID=46331236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201230553A SI2714740T1 (sl) | 2011-06-03 | 2012-05-31 | Nevtralizirajoče protitelo Mat3 receptorja prolaktina in njegova terapevtska uporaba |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9353186B2 (sl) |
| EP (2) | EP2530089A1 (sl) |
| JP (1) | JP5859641B2 (sl) |
| KR (1) | KR101920521B1 (sl) |
| CN (1) | CN103764679B (sl) |
| AP (1) | AP2013007266A0 (sl) |
| AR (1) | AR086631A1 (sl) |
| AU (1) | AU2012264765B2 (sl) |
| BR (1) | BR112013030995B1 (sl) |
| CA (1) | CA2837736C (sl) |
| CL (1) | CL2013003459A1 (sl) |
| CO (1) | CO6852025A2 (sl) |
| CR (1) | CR20130632A (sl) |
| CU (1) | CU20130163A7 (sl) |
| CY (1) | CY1117660T1 (sl) |
| DK (1) | DK2714740T3 (sl) |
| DO (1) | DOP2013000285A (sl) |
| EA (1) | EA029316B1 (sl) |
| EC (1) | ECSP13013063A (sl) |
| ES (1) | ES2572215T3 (sl) |
| HK (1) | HK1195081A1 (sl) |
| HR (1) | HRP20160506T1 (sl) |
| HU (1) | HUE028775T2 (sl) |
| IL (1) | IL229504B (sl) |
| MA (1) | MA35237B1 (sl) |
| ME (1) | ME02659B (sl) |
| MX (1) | MX343683B (sl) |
| PE (1) | PE20141158A1 (sl) |
| PL (1) | PL2714740T3 (sl) |
| RS (1) | RS54727B1 (sl) |
| SG (1) | SG195060A1 (sl) |
| SI (1) | SI2714740T1 (sl) |
| TN (1) | TN2013000501A1 (sl) |
| TW (1) | TWI548649B (sl) |
| UY (1) | UY34116A (sl) |
| WO (1) | WO2012163932A1 (sl) |
| ZA (1) | ZA201309683B (sl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2687974T3 (es) | 2012-03-14 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Moléculas multiespecíficas de unión a antígeno y uso de las mismas |
| CN105102480B (zh) | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| MY197218A (en) | 2015-07-06 | 2023-06-02 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| CN110382534B (zh) | 2016-11-29 | 2023-05-09 | 里珍纳龙药品有限公司 | 治疗prlr阳性乳腺癌的方法 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| CA3069193A1 (en) | 2017-07-10 | 2019-01-17 | Bayer Pharma Aktiengesellschaft | Prolactin receptor antibody for male and female pattern hair loss |
| KR20240015159A (ko) * | 2017-08-10 | 2024-02-02 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 |
| BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN116655791B (zh) * | 2023-05-06 | 2023-11-07 | 浙江触奇生物科技有限公司 | 一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| WO2003004989A2 (en) | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| WO2006110581A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| PT2059535E (pt) | 2006-08-18 | 2014-01-29 | Novartis Ag | Anticorpos específicos do prlr e suas utulizações |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
-
2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
-
2012
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en active Application Filing
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active IP Right Grant
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active Pending
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
-
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
-
2014
- 2014-08-18 HK HK14108441.2A patent/HK1195081A1/zh unknown
-
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-05-12 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1195081A1 (zh) | 中和性促乳素受體抗體 及其治療用途 | |
| IL264508B (en) | Humanized interleukin-6 and interleukin-6 receptor | |
| HK1180700A1 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| ZA201403264B (en) | Neutralizing gp41 antibodies and their use | |
| ZA201306451B (en) | Anti-il-6 receptor antibodies and methods of use | |
| LT2523688T (lt) | Antikūno kompozicija ir terapiniai režimai | |
| IL227355A0 (en) | Treatment preparations that combine a glucocorticoid receptor antagonist and a steroid | |
| EP2750508A4 (en) | COMPOUNDS AND THERAPEUTIC METHODS |